Nantahala Capital Management’s Neos Therapeutics, Inc NEOS Stock Holding History

Nantahala Capital Management’s Portfolio NEOS Stock Details NEOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,610,000	Closed	-$2.44M	–	130
2020 Q3	$2.44M	Hold	4,610,000	–	–	0.07%	96
2020 Q2	$3.16M	Hold	4,610,000	–	–	0.1%	94
2020 Q1	$3.46M	Hold	4,610,000	–	–	0.13%	81
2019 Q4	$6.96M	Hold	4,610,000	–	–	0.21%	59
2019 Q3	$6.82M	Hold	4,610,000	–	–	0.25%	63
2019 Q2	$5.95M	Buy	4,610,000 +125,000	+3%	+$230K	0.18%	70
2019 Q1	$11.7M	Hold	4,485,000	–	–	0.37%	49
2018 Q4	$7.4M	Buy	+4,485,000	New	+$12.6M	0.23%	62

Other funds holding NEOS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nantahala Capital Management's NEOS Position: Q4 2020 in Review

Nantahala Capital Management sold out of Neos Therapeutics, Inc (NEOS) in Q4 2020, closing a stake of 4,610,000 shares — an estimated $2.44M sold.

Nantahala Capital Management first reported a position in NEOS in Q4 2018 and held it in 8 quarters. The position peaked at $11.7M in Q1 2019. 37 funds tracked by Wall St. Rank hold NEOS as of Q4 2020.

Nantahala Capital Management reported no remaining Neos Therapeutics, Inc position as of Q4 2020 after selling out during the quarter.
Nantahala Capital Management sold 4,610,000 Neos Therapeutics, Inc shares in Q4 2020, an estimated $2.44M.
Nantahala Capital Management first reported a position in Neos Therapeutics, Inc in Q4 2018 and held it in 8 quarters.
Nantahala Capital Management's Neos Therapeutics, Inc position peaked at $11.7M in Q1 2019.
37 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q4 2020.

Based on Nantahala Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.